학술논문
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
Document Type
Journal
Author
Knop, Stefan; Langer, Christian; Engelhardt, Monika Martha; Bassermann, Florian; Schreder, Martin; Muegge, Lars-Olof; Schaefer-Eckart, Kerstin; Blau, Igor W.; Wolleschak, Denise; Reusch, Julia; von Metzler, Ivana; Metzner, Bernd; Dechow, Tobias; Hertenstein, Bernd; Duerk, Heinz; Theurich, Sebastian; Stuebig, Thomas; Kroenke, Jan; Held, Swantje; Einsele, Hermann; DSMM; German Myeloma Study Grp
Source
Subject
Language
English
ISSN
15277755